Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SNDXBearishIndustry Newsnews

High materiality7/10

Syndax's Axatilimab IPF trial misses endpoint; focus shifts to cGVHD readouts

Oct 12, 2026, 4:18 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Phase 2 failure in IPF lowers short-term confidence in axatilimab's IPF label expansion, pressuring near-term valuation; however, a non-deteriorating safety profile and de-risked cGVHD trials provide a partial offset.

AI summary

What happened, with direct paths to the underlying reporting

SYNDX announced that MAXPIRe in IPF did not meet the primary endpoint of annualized FVC decline, with safety comparable to placebo. Axatilimab remained well tolerated, and no new safety signals emerged. The company still has cGVHD trials with results expected later this year and in early 2028, keeping the pipeline on track despite IPF setback.

MAXPIRe IPF Phase 2 failed to meet primary endpoint: annualized FVC decline.
Axatilimab safety profile was comparable to placebo; no new safety signals.
cGVHD trials continue with results due later this year and in early 2028.
Near-term focus shifts to pipeline milestones; IPF setback may weigh valuation.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Syndax's Axatilimab IPF trial misses endpoint; focus shifts to cGVHD readouts

Syndax Stock Drops After Phase 2 IPF Trial Misses Primary Endpoint

US FDA approves Syndax's blood cancer drug

Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet